What Has Been The Historical And Current Growth Of The Calcium Channel Blocker Market?
The calcium channel blocker market has seen considerable growth due to a variety of factors.
• In recent times, the market size for calcium channel blocker has experienced robust growth. This market is forecasted to expand from $15.56 billion in 2024 to $16.62 billion in 2025, with a compound annual growth rate (CAGR) of 6.8%. The surge in growth during the historic period can be accredited to factors like a rise in cardiovascular diseases, older population, advancements in medical studies, lifestyle changes, and elevated consciousness.
What Is The Forecast For The Calcium Channel Blocker Market Size?
The Calcium Channel Blocker market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are pointed towards substantial growth in the calcium channel blocker market in the upcoming years. The market is projected to expand to $22.07 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.4%.
The growth anticipated in this period is due to the escalating global impact of cardiovascular diseases, the trend towards personalized medicine, better healthcare accessibility, broadened applications, official regulatory approvals, and market expansion. The forecast period is likely to see trends such as market growth, developments in technology, a changing regulatory environment, competitive analysis, evolving patient preferences, and increased awareness.
What Are The Essential Drivers Behind The Growth Of The Calcium Channel Blocker Market?
The escalating rate of occurrences of cardiovascular diseases is projected to spur the calcium channel blocker market's expansion. Cardiovascular disease is a term referring to conditions impacting the heart or blood vessels. Calcium channel blockers (CCBs) are employed to decrease the chances of heart failure and stroke. Therefore, a growth in the rate of cardiovascular diseases will lead to increased demand for calcium channel blockers. For example, in August 2022, a US-based non-profit medical organization, the American College of Cardiology, published a report indicating that all four cardiovascular risk factors will see an increase from 2025 to 2060 in the United States. The highest proportional upward swing can be noticed in diabetes at 39.3%, equivalent to 55 million people, followed by dyslipidemia (27.6% representing 126 million), hypertension (25.1% representing 162 million) and obesity (18.3% representing 126 million). The report also highlighted that the most significant anticipated surges in cardiovascular disease rates were in stroke (33.8% equal to 15 million), heart failure (33.4% reaching 13 million), ischemic heart disease (30.7% equal to 29 million), and heart attack (16.9% to 16 million). Hence, the escalating rate of occurrences of cardiovascular diseases is a key driving factor for the expansion of the calcium channel blocker market.
How Is The Global Calcium Channel Blocker Market Divided Into Key Segments?
The calcium channel blocker market covered in this report is segmented –
1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes
2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine
2) By Benzodiazepine: Diazepam
3) By Phenylalkylamine: Verapamil
4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine
Pre-Book The Calcium Channel Blocker Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Calcium Channel Blocker Market?
The calcium channel blocker market is witnessing a growing trend towards product innovation. The major firms in the market are concentrating on creating novel products to maintain their foothold. An illustration of this came in June 2022 when CMP Pharma, an American pharmaceutical manufacturer, introduced Norliqva. This product is the only oral liquid solution of the besylate salt of amlodipine, which is a long-lasting calcium channel blocker. Norliqva, uniquely, is an oral solution of amlodipine, designed to manage hypertension in anyone aged 6 or older. The product eliminates the concerns and inconsistencies associated with crushing or formulating amlodipine tablets, ensuring uniform dosage and bioequivalence. Norliqva is specifically designed for a group of patients in need of amlodipine, but struggle with swallowing or cannot swallow at all.
Who Are the Key Players In The Calcium Channel Blocker Market?
Major companies operating in the calcium channel blocker market include:
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Bausch Health Companies Inc.
• Lupin Pharmaceuticals Inc.
• Cadila Healthcare Limited
• Covis Pharma BV
• Glenmark Pharmaceuticals Inc.
• Amneal Pharmaceuticals LLC
• Sofgen Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Knoll Healthcare Private Limited
• Sanofi S.A.
• Clearsynth Labs Ltd.
• Searle LLC
• Bayer AG
• AstraZeneca plc
• Wyeth-Ayerst Lederle Inc.
• GlaxoSmithKline Plc.
• AbbVie Inc.
• Silvergate Pharmaceuticals Inc.
• Exela Pharma Sciences LLC
• Arbor Pharmaceuticals LLC
• Sun Pharmaceutical Industries Ltd.
What Are The Regional Insights Into The Calcium Channel Blocker Market?
North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
